Primary Ciliary Dyskinesia — Bronchiectasis, Situs Abnormalities & Infertility

Key Points

• Think PCD when chronic wet cough and nasal congestion begin in early childhood, especially with neonatal distress or laterality abnormalities.
• Normal situs does not exclude PCD.
• Very low nasal nitric oxide supports the diagnosis in appropriate patients but is not a stand-alone universal test.
• Genetic testing and ciliary structural/functional testing are complementary.
• Bronchiectasis can develop despite apparently mild childhood symptoms.
• Daily airway clearance and exercise are core long-term therapies.
• Use airway cultures to guide treatment of exacerbations and surveillance for Pseudomonas/NTM.
• Infertility and hearing problems are part of the multisystem phenotype.

Algorithm

1. Identify a compatible lifelong phenotype: neonatal respiratory distress, chronic wet cough, chronic nasal disease, laterality abnormality, bronchiectasis, or infertility.
2. Exclude or evaluate major mimics such as cystic fibrosis, immunodeficiency, aspiration, and non-PCD bronchiectasis.
3. Measure nasal nitric oxide using validated methodology when age and clinical context are appropriate.
4. Order an extended PCD genetic panel and refer to an experienced diagnostic center.
5. Use TEM, immunofluorescence, or high-speed video microscopy when needed to resolve diagnosis.
6. Obtain baseline spirometry, chest imaging, airway cultures, ENT/audiology assessment, and laterality documentation.
7. Start daily airway-clearance therapy, exercise, vaccination, and culture-directed treatment of exacerbations.
8. Provide long-term surveillance for lung function, microbiology, hearing, sinus disease, fertility, and advanced lung disease.

Clinical Synopsis & Reasoning

Primary ciliary dyskinesia (PCD) should be considered in patients with a lifelong pattern of wet cough, chronic nasal congestion, recurrent otitis or sinus disease, unexplained neonatal respiratory distress, bronchiectasis, laterality abnormalities, or infertility. The core defect is impaired motile-cilia function. Because motile cilia are essential in the respiratory tract, embryologic left-right patterning, ependymal flow, and reproductive tracts, the phenotype extends beyond the lungs.

Four clinical features are especially useful in raising pretest probability: unexplained neonatal respiratory distress in a term infant, year-round daily wet cough beginning early in life, year-round daily nasal congestion beginning early in life, and an organ laterality abnormality such as situs inversus or heterotaxy. Roughly half of patients have laterality defects, so normal organ position does not exclude PCD. Kartagener syndrome refers to the combination of PCD, chronic sinus disease/bronchiectasis, and situs inversus, but it represents only part of the PCD spectrum.

High-resolution chest CT may show bronchiectasis, mucus plugging, and chronic atelectatic change, often with middle/lower-lobe predominance. Chronic otitis media can cause conductive hearing loss. Male infertility commonly reflects immotile sperm; female fertility may be reduced due to impaired fallopian-tube ciliary function and ectopic pregnancy risk may be increased.

Diagnosis is challenging because there is no single universally definitive test. In cooperative patients with a compatible phenotype, nasal nitric oxide is typically very low and is a useful diagnostic tool when measured with validated techniques and after excluding confounders such as acute viral infection. Extended genetic panels can identify pathogenic variants in many patients. Transmission electron microscopy can demonstrate classic ultrastructural defects but can be normal in genetically confirmed disease. High-speed video microscopy and immunofluorescence are used in specialized centers. A normal sweat chloride or CFTR evaluation helps distinguish cystic fibrosis when the phenotype overlaps.

The major reasoning error is to equate situs inversus with PCD or, conversely, to exclude PCD when situs is normal. The diagnosis depends on the full lifelong phenotype plus validated testing in an experienced center.

Treatment Strategy & Disposition

PCD treatment aims to preserve lung function by improving airway clearance and aggressively managing respiratory infections. Daily airway-clearance therapy is a cornerstone. Techniques may include chest physiotherapy, positive expiratory pressure devices, oscillatory devices, and regular aerobic exercise. Unlike diseases in which cough is weak, many PCD patients can generate an effective cough once mucus is mobilized.

Respiratory exacerbations are treated with antibiotics guided by prior and current airway cultures. Common childhood pathogens include Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis; Pseudomonas and other gram-negative organisms become increasingly important in chronic bronchiectasis. Surveillance cultures help choose therapy and identify new pathogens. Long-term macrolide therapy may be considered in selected patients with frequent exacerbations, balancing benefit against resistance, QT effects, and nontuberculous mycobacterial considerations.

Upper-airway care includes saline irrigation, treatment of sinus disease, and coordinated ENT/audiology follow-up. Tympanostomy decisions are individualized because chronic drainage can be problematic. Standard immunizations should be current, including respiratory vaccines appropriate to age and risk. Tobacco smoke and other airway irritants should be avoided.

There is no established role for routine inhaled corticosteroids unless asthma or another inflammatory indication exists, and bronchodilators are individualized. Dornase alfa is not routinely recommended by analogy with cystic fibrosis because evidence in non-CF bronchiectatic disease does not support indiscriminate use. Fertility counseling is important; assisted reproductive technologies can be effective.

Patients with severe respiratory decline, refractory infection, hemoptysis, hypoxemic failure, or advanced bronchiectasis may need hospitalization, IV antibiotics, bronchoscopy, or transplant evaluation. Long-term care is best coordinated through a multidisciplinary PCD center.

Epidemiology / Risk Factors

• PCD is genetically heterogeneous, with many causative genes affecting ciliary structure or function.
• Laterality abnormalities occur in a substantial but not universal subset.
• Diagnosis is often delayed because chronic cough and sinus disease are mislabeled as recurrent infection or asthma.
• Both pediatric and adult patients can present for the first time with established bronchiectasis.

Investigations

PCD Diagnostic Clues

Pharmacology

Prognosis / Complications

• Earlier diagnosis and consistent airway clearance are associated with better preservation of respiratory health.
• Bronchiectasis and chronic airway infection can progress over time.
• Some patients develop severe lung disease requiring transplantation.
• Fertility impairment is common but does not preclude successful assisted reproduction.

Patient Education / Counseling

• Explain that PCD affects motile cilia throughout the body, which is why lung, sinus, ear, laterality, and fertility findings can occur together.
• Teach a daily airway-clearance plan and how to recognize a respiratory exacerbation.
• Encourage regular exercise and avoidance of tobacco smoke or vaping.
• Review the importance of culture-guided antibiotics and avoiding unnecessary repeated empiric therapy.
• Discuss fertility and reproductive options before family planning becomes urgent.

Notes

The value of a PCD article is that it links several otherwise separate clues into one mechanism. A patient with chronic sinus disease, bronchiectasis, infertility, and situs abnormalities does not have four unrelated problems; each can arise from dysfunctional motile cilia.

The diagnostic approach should be center-based and multimodal. No single negative test reliably excludes all genetic forms. Once the diagnosis is established, the management emphasis is less about a disease-specific drug and more about disciplined longitudinal care: airway clearance, microbiology, early treatment of exacerbations, hearing/ENT care, exercise, fertility counseling, and surveillance for progression.

References

1. ATS Clinical Practice Guideline — Diagnosis of Primary Ciliary Dyskinesia — Link
2. Shapiro AJ, et al. PCD Foundation Consensus Recommendations for Diagnosis, Monitoring and Treatment — Link
3. Primary ciliary dyskinesia: national expert consensus statement on standards of care (2026) — Link